JP2022527126A - H因子ベクターおよびその使用 - Google Patents

H因子ベクターおよびその使用 Download PDF

Info

Publication number
JP2022527126A
JP2022527126A JP2021560050A JP2021560050A JP2022527126A JP 2022527126 A JP2022527126 A JP 2022527126A JP 2021560050 A JP2021560050 A JP 2021560050A JP 2021560050 A JP2021560050 A JP 2021560050A JP 2022527126 A JP2022527126 A JP 2022527126A
Authority
JP
Japan
Prior art keywords
nucleic acid
isolated nucleic
seq
factor
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021560050A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022527126A5 (cg-RX-API-DMAC7.html
Inventor
ガオ,グアンピン
シエ,ジュン
Original Assignee
ユニバーシティ オブ マサチューセッツ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユニバーシティ オブ マサチューセッツ filed Critical ユニバーシティ オブ マサチューセッツ
Publication of JP2022527126A publication Critical patent/JP2022527126A/ja
Publication of JP2022527126A5 publication Critical patent/JP2022527126A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2021560050A 2019-04-10 2020-04-09 H因子ベクターおよびその使用 Pending JP2022527126A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962831870P 2019-04-10 2019-04-10
US62/831,870 2019-04-10
PCT/US2020/027452 WO2020210480A2 (en) 2019-04-10 2020-04-09 Factor h vectors and uses thereof

Publications (2)

Publication Number Publication Date
JP2022527126A true JP2022527126A (ja) 2022-05-30
JP2022527126A5 JP2022527126A5 (cg-RX-API-DMAC7.html) 2023-04-18

Family

ID=72750649

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021560050A Pending JP2022527126A (ja) 2019-04-10 2020-04-09 H因子ベクターおよびその使用

Country Status (10)

Country Link
US (2) US12570997B2 (cg-RX-API-DMAC7.html)
EP (1) EP3966231A4 (cg-RX-API-DMAC7.html)
JP (1) JP2022527126A (cg-RX-API-DMAC7.html)
KR (1) KR20210149803A (cg-RX-API-DMAC7.html)
CN (1) CN113924313A (cg-RX-API-DMAC7.html)
AU (1) AU2020272875A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021019032A2 (cg-RX-API-DMAC7.html)
CA (1) CA3135367A1 (cg-RX-API-DMAC7.html)
IL (1) IL287071A (cg-RX-API-DMAC7.html)
WO (1) WO2020210480A2 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3359663A4 (en) 2015-09-24 2019-08-14 The Trustees of The University of Pennsylvania COMPOSITION AND METHOD FOR THE TREATMENT OF A COMPLEMENT-MEDIATED DISEASE
IL315695A (en) * 2022-03-18 2024-11-01 Univ Florida Methods and compositions for treating RBM20-associated cardiomyopathy with a viral vector

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016531910A (ja) * 2013-08-16 2016-10-13 アレクシオン ファーマシューティカルズ, インコーポレイテッド 移植前の臓器への補体阻害剤の投与による移植拒絶の処置
WO2018106956A2 (en) * 2016-12-07 2018-06-14 University Of Florida Research Foundation, Incorporated IL-1RA CDNAs
JP2018527941A (ja) * 2015-09-24 2018-09-27 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 補体媒介性疾患を処置するための組成物及び方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2561073T3 (en) * 2010-04-23 2016-12-12 Univ Massachusetts Aav vectors targeted to central nervous system and methods of use thereof
CA2988471A1 (en) * 2015-07-28 2017-02-02 University Of Massachusetts Transgenic expression of dnase i in vivo delivered by an adeno-associated virus vector
WO2017024198A1 (en) 2015-08-06 2017-02-09 The Trustees Of The University Of Pennsylvania Glp-1 and use thereof in compositions for treating metabolic diseases

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016531910A (ja) * 2013-08-16 2016-10-13 アレクシオン ファーマシューティカルズ, インコーポレイテッド 移植前の臓器への補体阻害剤の投与による移植拒絶の処置
JP2018527941A (ja) * 2015-09-24 2018-09-27 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 補体媒介性疾患を処置するための組成物及び方法
WO2018106956A2 (en) * 2016-12-07 2018-06-14 University Of Florida Research Foundation, Incorporated IL-1RA CDNAs

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GENE THER., vol. 18, no. 4, JPN6024012530, April 2011 (2011-04-01), pages 403 - 410, ISSN: 0005293844 *
MOLECULAR THERAPY, vol. 22, no. 4, JPN6024012529, 2014, pages 693 - 701, ISSN: 0005293845 *

Also Published As

Publication number Publication date
AU2020272875A1 (en) 2021-10-14
WO2020210480A3 (en) 2020-11-12
IL287071A (en) 2021-12-01
EP3966231A2 (en) 2022-03-16
KR20210149803A (ko) 2021-12-09
WO2020210480A2 (en) 2020-10-15
US20260226507A1 (en) 2026-08-06
CA3135367A1 (en) 2020-10-15
CN113924313A (zh) 2022-01-11
US20220162641A1 (en) 2022-05-26
WO2020210480A9 (en) 2021-01-14
EP3966231A4 (en) 2022-12-21
BR112021019032A2 (pt) 2022-01-11
US12570997B2 (en) 2026-03-10

Similar Documents

Publication Publication Date Title
US12467063B2 (en) Recombinant AAV vectors useful for reducing immunity against transgene products
JP2022528010A (ja) メープルシロップ尿症(msud)のaav媒介遺伝子治療
JP2022529782A (ja) シュタルガルト病(abca4)の遺伝子治療
JP7397488B2 (ja) Sod1二重発現ベクターおよびその使用
US12478692B2 (en) Gene therapy for spinal muscular atrophy
US20230057380A1 (en) Recombinant adeno-associated virus for delivery of kh902 (conbercept) and uses thereof
US20220202959A1 (en) Gene therapies for usher syndrome (ush2a)
US20260139249A1 (en) Gene replacement therapy for foxg1 syndrome
US12553063B2 (en) CAS13 family AAV vectors and uses thereof
JP2021520811A (ja) ヘキソサミニダーゼアルファおよびベータサブユニットをコードしているバイシストロニックaavベクターならびにその使用
US20220403417A1 (en) Aav-based delivery of thymine kinase 2
US12570997B2 (en) Factor H vectors and uses thereof
JP2024515823A (ja) メープルシロップ尿症(msud)におけるbcaa修飾のための遺伝子治療
WO2023147584A2 (en) Compositions and methods for treating sialidosis
US20250320503A1 (en) Aav vectors encoding sod1-targeting artificial mirnas (ami-rna)
CN118284698A (zh) 脊髓性肌萎缩症的基因疗法
WO2022232117A1 (en) Direct raav-mediated in vivo gene editing of hematopoietic stem cells

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230410

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230410

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240319

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240401

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240701

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241001

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241213

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250616